ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

Review of current and emerging treatments for older adults with acute myeloid leukemia, highlighting venetoclax plus ...

In updated 2025 American Society of Hematology guidelines, recommendations are presented for the management of newly ...

Measurable residual disease after induction therapy may serve as an individual-level predictor of survival among patients ...

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise ...

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50. Despite considerable advances during the past 20 years in the diagnostic ...